LPCN vs. PYXS, BMEA, INCR, ABOS, IMUX, IKNA, MNOV, IZTC, ADAP, and IGMS
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Pyxis Oncology (PYXS), Biomea Fusion (BMEA), InterCure (INCR), Acumen Pharmaceuticals (ABOS), Immunic (IMUX), Ikena Oncology (IKNA), MediciNova (MNOV), Invizyne Technologies (IZTC), Adaptimmune Therapeutics (ADAP), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry.
Lipocine vs. Its Competitors
Lipocine (NASDAQ:LPCN) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.
9.1% of Lipocine shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 6.4% of Lipocine shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Lipocine's return on equity of -26.68% beat Pyxis Oncology's return on equity.
Lipocine has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
In the previous week, Pyxis Oncology had 1 more articles in the media than Lipocine. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for Lipocine. Lipocine's average media sentiment score of 0.00 equaled Pyxis Oncology'saverage media sentiment score.
Lipocine has higher revenue and earnings than Pyxis Oncology. Lipocine is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Lipocine currently has a consensus target price of $9.00, indicating a potential upside of 189.39%. Pyxis Oncology has a consensus target price of $9.00, indicating a potential upside of 689.47%. Given Pyxis Oncology's higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than Lipocine.
Summary
Lipocine beats Pyxis Oncology on 7 of the 13 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
This page (NASDAQ:LPCN) was last updated on 7/7/2025 by MarketBeat.com Staff
Free LPCN Stock Alerts